I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to:

THE TRADEMAN Commissioner for Patents, Washington, D.C. 20231.

Date of Signature and Deposit:

Attorney of Record

Hector F. DeLuca, et al. 09/769,579 January 25, 2001 METHOD OF TREATMENT OF TYPE I IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Serial No.:

Filed:

For:

Group Art Unit:

Examiner:

Commissioner For Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, enclosed herewith is a list of documents which the Applicants in the aboveidentified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application.

U.S. Patents

5,190,935; Binderup, et al.; March 2, 1993.

5,665,387; Mathieu, et al.; September 9, 1997.

6,004,987; Demarchez, et al.; December 21, 1999.

Foreign Patents

WO 90/09991; Calverley, et al.; September 7, 1990.

WO 91/00271; Calverley, et al.; January 10, 1991.

04/16/2003 HVUDNG1 00000092 170055 09769579 WO 01/9221 A1; DeLuca, et al.; December 6, 2001.

Other Documents

A. Al-Qadreh, et al., "Treatment of Osteopenia in Children with Insulin-Dependent Diabetes Mellitus: the Effect of 1α -Hydroxyvitamin D_3 ," <u>Eur. J. Pediatr.</u> 155:15-17, 1996.

C. Mathieu, et al., "Prevention of Type I Diabetes in Nod Mice by 1,25 Dihydroxyvitamin D_3 and its Analogues," Proceedings of the Workshop on Vitamin D, pp. 540-548, 1994.

Y. Yoshida, et al., "A Randomized Study of Alfacalcidol in the Refractory Myelodysplastic Anaemias.

A Japanese Cooperative Study," Int. J. Clin. Pharm. Res.

XIII(1):21-27, 1993.

Applicants believe a fee is necessary to enter this Supplemental Information Disclosure Statement and direct that fee be charged to Deposit Account 17-0055. If any additional fees are necessary, please charge Deposit Account 17-0055.

Respectfully submitted,

Hector F. DeLuca, et al.

April 11, 2003

Jean C. Baker

Reg. No. 35,433

Quarles & Brady LLP

411 East Wisconsin Avenue Milwaukee, WI 53202-4497

(414) 277-5709



Approved for use Intrograf 107 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid Complete if Known FEE TRANSMITTAL Application Number 09/769,579 January 25, 2001 Filing Date for FY 2003 Hector F. DeLuca First Named Inventor Patent fees are subject to annual revision. **Examiner Name** K. Stiller Applicant claims small entity status. See 37 CFR 1.27 Group Art Unit 1617 TOTAL AMOUNT OF PAYMENT (\$) 180.00960296.95700 Attorney Docket No. FEE CALCULATION (continued) METHOD OF PAYMENT (check all that apply) Money Order 3. ADDITIONAL FEES Other None Check Credit card Large Entity Small Entity ✓ Deposit Account: Fee Fee Code (\$) Fee Paid Fee Fee Code (\$). Fee Description Deposit 17-0055 Numbe 1051 130 2050 65 Surcharge - late filing fee or oath Deposit Quarles & Brady LLP 2052 Surcharge - late provisional filing fee or cover sheet 1052 50 25 The Commissioner is authorized to: (check all that apply) 1053 130 1053 4 130 Non-English specification Charge fee(s) indicated below Credit any overpayments 1812 2,520 1812 2,520 For filing a request for ex parte reexamination Charge any additional fee(s) during the pendency of this application 1804 920 1804 920* Requesting publication of SIR prior to Examiner action Charge fee(s) indicated below, except for the filing fee to the above identified deposit account Requesting publication of SIR after Examiner action 1805 1,840*1805 1,840* **FEE CALCULATION** Extension for reply within first month 1251 110 2251 55 1. BASIC FILING FEE Extension for reply within second month 1252 410 2252 205 Large Entity | Small Entity Fee Description 1253 930 2253 Extension for reply within third month Fee Paid Code (\$) Code (\$) 1254 1.450 2254 Extension for reply within fourth month 725 1001 750 2001 375 Utility filing fee 1255 1,970 2255 985 Extension for reply within fifth month 1002 330 2002 165 Design filing fee 1401 320 2401 160 Notice of Appeal 2003 260 1003 520 Plant filing fee 1402 320 2402 160 Filing a brief in support of an appeal 1004 750 2004 375 Reissue filing fee Provisional filing fee 1403 280 2403 140 Request for oral hearing 1005 160 2005 80 1451 1,510 1451 1,510 Petition to institute a public use proceeding SUBTOTAL (1) (\$) 0.00 1452 110 2452 Petition to revive - unavoidable 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1453 1,300 2453 650 Petition to revive - unintentional Fee Paid 1501 1,300 2501 650 Utility issue fee (or reissue) Extra Claims below 0.00 2502 Х 1502 470 235 Design issue fee Total Claims Independent Claims 0.00 1503 630 2503 315 Plant issue fee Multiple Dependent 1460 130 1460 130 Petitions to the Commissioner 1807 50 1807 50 Processing fee under 37 CFR 1.17(q) Large Entity Small Entity 180.00 1806 180 1806 180 Submission of Information Disclosure Stmt Fee Description Code (\$) Code (\$) Recording each patent assignment per property (times number of properties) 40 B021 8021 40 1202 18 2202 9 Claims in excess of 20 750 2809 375 1809 Filing a submission after final rejection (37 CFR § 1.129(a)) 1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple dependent claim, if not paid For each additional invention to be examined (37 CFR § 1.129(b)) 750 2810 375 1810 * Reissue independent claims 1204 84 2204 42 over original patent Request for Continued Examination (RCE) 1801 750 2801 375 ** Reissue claims in excess of 20 1205 18 2205 Request for expedited examination of a design application 900 1802 (\$) 0.00 Other fee (specify) SUBTOTAL (2) (\$) 180.00 SUBTOTAL (3) *Reduced by Basic Filing Fee Paid **or number previously paid, if greater; For Reissues, see above

SUBMITTED BY			A A			Complete (if applicable)	
Name (Print/Type)	Jean C, Baker	20	Registration No. (Attorney/Agent)	35,433	Telephone	414-277-5709	
Signature	MULL	. Die	1		Date	April 11, 2003	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.